Announcement PDF ASX Announcement Race SPP Closing Deadline Reminder and Investor Briefing Recording  Applications under the Race Share Purchase Plan for eligible shareholders will close this Friday 17 December 2021 at 8:00pm AEDT (Sydney time)  Shareholders that wish to participate are advised to submit their application with sufficient time for funds to clear  View the instructions below for information on how to access the SPP offer details and how applications can be submitted electronically  Recording from the recent Investor Q+A session is available. 14 December 2021 – Race Oncology Limited (“Race”) wishes to remind shareholders that applications for the Share Purchase Plan (SPP) under which eligible shareholders can subscribe for up to $30,000 in new Race shares, will close this Friday, 17 December 2021 at 8:00pm AEDT (Sydney time.) Any shareholders that have not received their paperwork can apply electronically. Instructions on how to download the SPP Booklet and personalised application form online, and how to register for an online account with Automic, are set out below: I already have an online account with Automic I do not have an online account with Automic and wish to access one time only I do not have an online account with Automic and want to register 1. Visit: https://investor.automic.co m.au/#/home 1. Visit: https://investor.automic.com.au/#/sig nup 1. Visit: https://investor.automic.com.au/#/log insah 2. Under Existing users sign in enter your established username and password. 2. Select Race Oncology Limited from the dropdown list in the Issuer Name Field. 2. Select Race Oncology Limited from the dropdown list in the Issuer Name Field. 3. Once you have successfully logged in, click on: Documents & Statements > download next to the SPP Booklet and Application Form. 3. Enter your Holding Number (SRN/HIN). 3. Enter your Holding Number (SRN/HIN). 4. Enter your postcode OR country of residence (only if outside Australia). 4. Enter your postcode OR country of residence (only if outside Australia). 5. Tick the box "I'm not a robot" and then select "Next". 5. Tick the box "I'm not a robot" and then select "Access". 6. Complete the prompts to set up your username and password details. 6. Once you have successfully logged in, click on: Documents & Statements > download next to the SPP Booklet and Application Form 7. Once you have successfully logged in, click on: Documents & Statements > download next to the SPP Booklet and Application Form Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com Race invites any shareholders that are interested in participating, but experiencing difficulty with the process, to contact the Company’s share registrar, Automic Registry Services via 1300 288 664 or hello@automicgroup.com.au. Race Oncology’s CEO and Managing Director, Mr Phillip Lynch commented, “We are grateful to all those shareholders that have participated in the SPP to date and are encouraged by the support received. We recommend any shareholder wishing to participate applies as soon as possible, to ensure their funds can clear in time to meet the application deadline. We understand that some shareholders who have not registered to received company paperwork by email have not yet received their paperwork via Australia Post. If you have not received the SPP documentation, the application process can be completed fully using the electronic form available via our website.” Further information on the SPP can also be found on Race’s SPP website at https://spp.raceoncology.com. Investor briefing recording A shareholder information session was held last week (ASX announcement: 30 November 2021). Investors are invited to watch the recording via the following link: https://www.raceoncology.com/race-oncology-qa-session/. This announcement was authorised for release by Phillip Lynch, CEO & Managing Director. -ENDS- About Race Oncology (ASX: RAC) Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®. Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery. The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML). Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com Release authorised by: Media contact: Phil Lynch, CEO/MD on behalf Jane Lowe of the Race Board of Directors +61 411 117 774 phillip.lynch@raceoncology.com jane.lowe@irdepartment.com.au Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com